Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A basket study in selected advanced solid tumors
NL-OMON52069Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vibostolimab and pembrolizumab in biliary cancer, transitional cell carcinoma (TCC), Cervical Cancer (CC) and 7 more, sponsored by Merck & Co. Started Dec 2021; status: recruiting.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
biliary cancertransitional cell carcinoma (TCC)Cervical Cancer (CC)endometrial cancer (EC)esophageal cancer
Beyond the preview
Go deeper on NL-OMON52069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52069.